Monthly Archives: August 2020

Voycare Announces 2020 Second Quarter Financial Reports and Disclosure Statements

COVINA, CA / ACCESSWIRE / August 19, 2020 / North America Frac Sand, Inc. dba Voycare (OTC PINK:NAFS) ("NAFS", "Voycare" or "Company"), a California-based telemedicine service provider and Chinese language digital health platform exclusively dedicated to women's health, today announces financial results for the second quarter of 2020. The Company's total revenues were $326,875 for the second quarter, as compared to $0.00 revenue reported for the same period in 2019. This was an increase of $326,875 when compared to the second quarter of 2019. The Company's total revenues for the six months ended June 30, 2020 were $540,894, as compared to $0.00 for the six months ended June 30, 2019. This was an increase of $540,894 when compared to the six months ended June 30, 2019.

To view the 2020 Second Quarter Financial Report and Disclosure Statement, please click below:

https://backend.otcmarkets.com/otcapi/company/financial-report/255497/content

"We are pleased to report positive earnings during this past second quarter despite challenges facing many businesses during this turbulent year," said Hong Cheng, CEO of Voycare. "We remain committed to building a strong Chinese language digital health platform for women around the world, providing access to quality health care. We feel optimistic for our space and product, and look forward to taking advantage of growth opportunities as they arise that can further maximize value for our clients, investors and shareholders."

The Company is currently developing new modules for its client-side dashboard as it continues a closed beta testing prior its September debut and official entry into China's rapidly growing telemedicine industry. China's tele-health market size is 700 billion RMB or approximately $US100 billion by the end of 2020 according to according to Phoenix News Media.

The Company has also recently began vetting Medical Directors to serve on its Board of Directors, and expects to share more updates in the weeks to come.

For more information about Voycare, please visit, www.voycare.com or follow us on Twitter @nafsvoycare.

About Voycare

North America Frac Sand, Inc. (OTC: NAFS) dba Voycare is a California based telemedicine service provider and Chinese language digital health platform exclusively dedicated to women's health in Asia, with the primary focus on China. Voycare is creating a new type of cross border health care experience for women by leveraging telehealth and the gig-economy, giving women a voice when making the right health care decision for themselves and their families. Voycare currently focuses on two important areas in women's health, Counseling and Fertility. Founded in 2019, Voycare has offices in Los Angeles and Shanghai.

Safe Harbor Statement

This news release contains certain forward-looking information. All information, other than information regarding historic fact that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future is forward-looking information. The forward-looking information contained in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. The forward-looking information contained in this news release is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from current expectations. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable law, the Company disclaims any obligation to update or modify such forward-looking information, either because of new information, future events or for any other reason. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein.

Contact Information
Voycare
+1.626.784.5846
info@voycare.com
www.voycare.com

SOURCE: North America Frac. Sand Inc. / Voycare

ReleaseID: 602367

Rising Prevalence of Respiratory Disorders Fuels Demand for Sinus Therapeutic Drugs: Future Market Insights

DUBAI, UAE / ACCESSWIRE / August 19, 2020 / According to a new market study by Future Market Insights (FMI), the sinus therapeutic drugs market will expand at a healthy CAGR of 6.3% between 2020 and 2030.

As a result of unhealthy lifestyles, immunity levels have decreased substantially among people across the globe. This in turn has increased the prevalence of common cold, which has been majorly attributed as the cause of sinus infections. The rising incidence of sinus among adults and children alike is expected to drive the demand for sinus therapeutic drugs.

Advancements in the field of biologics are playing a crucial role in the growth of the market. On these lines, Omalizumab, a medication originally designed to reduce sensitivity to allergens, is gaining remarkable traction among researchers and drug manufacturers. Omalizumab has received approval for usage in Europe and the US in the treatment of severe allergic asthma. This is expected to fuel the growth of the sinus therapeutic drug market.

"Owing to the outbreak of COVID-19, market players are expediting the production of drugs since it's a known fact that disorders in the respiratory tract increase the risk of contracting the virus. This is likely to offer lucrative revenue opportunities", opines FMI analyst.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-12367

Sinus Therapeutic Drugs Market – Key Takeaways

Sinus therapeutic drugs market is projected to surpass a global valuation of US$ 4.29 Bn by the end of 2030
Steroid nasal sprays accounted for the majority of share in 2019 and will remain the dominant segment through the forecast period.
Among the different classes of drugs, antibiotics remain the most sought-out drugs and the segment is forecasted to grow at a steady pace through 2030
The oral route of administration remains the most preferred during the treatment.

Sinus Therapeutic Drugs Market – Key Trends

The Covid-19 outbreak has asserted the market players to focus on nasal drug delivery, thus catalyzing the growth.
An increasing number of approvals by regulatory bodies are expected to boost the growth of the market in the forthcoming years.

Sinus Therapeutic Drugs Market – Regional Analysis

North America and Europe are expected to cumulatively account for nearly half of the global market value, with the former holding more than 30% in 2019.
Asia Pacific is forecasted to register tremendous growth during the forecast period, owing to poor air quality in the region which has been attributed to numerous respiratory diseases, including sinus.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-12367

Sinus Therapeutic Drugs Market – Competitive Landscape

Some of the major players operating in the market include Sun Pharmaceutical Industries, Inc., Reddy's Laboratories, Inc., Novartis AG, Tea Pharmaceutical Industries Ltd., Pfizer Inc., Fresenius Kabi USA, and Janssen Pharmaceuticals, Inc. Market players are focusing on obtaining an approval on their novel drugs to gain revenue opportunities. On these lines:

In Jan 2019, Dr. Reddy's Laboratories Ltd., along with Promius Pharma LLC announced the approval of their drug named TOSYMRA to treat acute migraines.
Janssen submitted the Esketamine Nasal Spray novel drug application to the US FDA to restore connections between neural cells in those suffering from depression.

Request a Discount for this Report@ https://www.futuremarketinsights.com/request-discount/rep-gb-12367

Sinus Therapeutic Drugs Market – Taxonomy

Drug Class:

Аntіhіѕtаmіnеѕ
Аnаlgеѕісѕ
Ѕulрhоnаmіdеѕ
Соrtісоѕtеrоіdѕ
Аntіbіоtісѕ
NSAID's
Оthеr Drug Сlаѕѕеѕ

Type of disease

Acute Sinusitis
Sub-acute Sinusitis
Chronic Sinusitis

Route of administration

Oral
Topical
Injectable

Distribution channel

Hospital pharmacies
Retail pharmacies
Online pharmacies

Region:

North America

U.S
Canada

Latin America

Brazil
Mexico
Argentina
Rest of Latin America

Europe

EU-5
BENELUX
Russia
Poland
Rest of Europe

South Asia

India
Pakistan
Sri Lanka

East Asia

China
Japan
South Korea

Oceania

Australia
New Zealand

Middle East & Africa

GCC
Turkey
South Africa
Rest of MEA

Get Market Alerts on Topics that you are Interested in@ https://www.futuremarketinsights.com/get-market-alerts/rep-gb-12367

Get Valuable Insights into Sinus Therapeutic Drugs Market

Future Market Insights, in its new offering, provides an unbiased analysis of the global sinus therapeutic drugs market, presenting historical demand data (2015-2019) and forecast statistics for the period from 2020-2030. The study divulges compelling insights on the sinus therapeutic drugs market, allowing readers to glean qualitative and quantitative information which will enable them to make informed market decisions in the upcoming forecast period.

Explore Extensive Coverage on FMI's Healthcare, Pharmaceuticals, and Medical Devices Landscape

Automated Cell Culture Systems Market: FMI's compelling study on the automated cell culture systems market sheds light on the prominent dynamics influencing the growth trajectory for the upcoming forecast period 2020-2030 through detailed segmental and regional analyses.

Orthotic Devices, Casts, and Splints Market: The orthotic devices, casts and splints market report offers a 360-degree analysis, bringing to the fore insights that can help stakeholders identify key challenges and opportunities across the upcoming decade's growth trajectory.

Cancer Care Products Market: The global cancer care products market is anticipated to surpass an impressive revenue threshold by the end of the forecast period ranging from 2020 to 2030, concludes FMI's recently published research report on the market.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Report: https://www.futuremarketinsights.com/reports/sinus-therapeutic-drugs-market
Press Release Source: https://www.futuremarketinsights.com/press-release/sinus-therapeutic-drugs-market

SOURCE: Future Market Insights

ReleaseID: 602387

Port San Antonio Strengthens America’s Standing as World’s Innovation Leader

Unique state-of-the-art facility will build on proven strategy that has already deployed numerous tech breakthroughs while creating thousands of strong careers in South Texas.

SAN ANTONIO, TX / ACCESSWIRE / August 18, 2020 / Port San Antonio, the big technology campus that is home to leading aerospace, cybersecurity, defense, robotics, and other advanced operations, continues to accelerate the pace of American ingenuity.

https://vimeo.com/447244515/317dcd7835

On August 13 the Port San Antonio Board of Directors approved construction of a full spectrum innovation center that will significantly advance the organization's Tech Port vision, which is based on three core principles:

Connect people with employment, educational and entrepreneurial opportunities.
Connect education at all levels with industry.
Connect technology innovators with domestic and international markets.

Today, the campus is home to over 14,000 jobs, of which nearly 4,000 have been added by the Port's tenant customers since the Tech Port vision was launched in 2018.

The upcoming space will be a leading destination that engages hundreds of thousands of people annually from throughout the region, across the country and around the world. They will include competitors and spectators of major esports events; students and their families participating in entertainment, cultural and learning experiences; and leading experts who will use the facility to collaborate while they create, showcase and sell their latest technological innovations.

The new building will span 130,000 square feet. Project costs will total approximately $60 million. It will be funded through a commercial loan, which the Port will repay through multiple revenue streams generated by the facility, including entertainment events, conferences, and industry partnerships.

To further bolster the Port's economic development mandate, the Board of Directors has also directed that profits from the innovation center will support technology-focused K-12, college-level and professional development programs.

The building's key components under a single roof will serve multiple functions simultaneously. They are:

A 2,500-seat state-of-the-art technology arena that can be configured for different uses, including esports competitions, concerts, product launches and large training programs. Retractable seating will allow the space to host conventions and conferences.
Space that will serve as the new home of the San Antonio Museum of Science and Technology (SAMSAT), which will host numerous hands-on exhibits, demonstrations and classes. The area will also serve to showcase current technologies as part of educational programs and to help companies demonstrate their innovations to prospective buyers.
Integrated classrooms and meeting spaces to further support educational programs, smaller industry meetings and collaboration among different partners and their clients.
A research and development lab that will provide scalable space and prototyping / fabrication equipment to support the work of startups. It will also allow greater collaboration between technology companies of all sizes with universities and other research partners to advance specific projects.
As a leading destination and community gathering space for a wide range of users, the facility will also feature a large 24-hour electronic gaming area and a full-scale food hall, including catering support for the various events hosted at the center.

Rendering of exterior of upcoming innovation center at Port San Antonio (credit: Port San Antonio / RVK Architects)

Rendering of technology arena at upcoming innovation center at Port San Antonio (credit: Port San Antonio / RVK Architects)

Rendering – as a destination that can host thousands of people simultaneously, the upcoming innovation center will include amenities such as an expansive food hall
(credit: Port San Antonio / RVK Architects)

Floor plan of upcoming innovation center at Port San Antonio (credit: Port San Antonio / RVK Architects)

Integrated virtual technology throughout the facility will give it global reach. Features will include teleconferencing systems that facilitate greater collaboration among researchers and educational institutions. It will also be equipped with broadcasting capabilities to stream entertainment and other content developed at the innovation center in real-time to audiences that could number in the millions.

The innovation center's feasibility analysis, business plan and design were developed over the course of nearly two years by the Port and American Triple I Partners-a fund management firm overseeing major development projects nationwide.

Construction will begin this summer, with completion scheduled for early 2022. It will be led by Sundt Construction with designs created by San Antonio-based RVK Architects.

Upon completion, the innovation center will be operated by ASM Global. The Los Angeles -based company manages over 300 stadiums, convention centers, theaters, and unique venues around the world. It also specializes in organizing its hosted activities, which include conventions, sporting events, gaming competitions, and concerts, as well as business, cultural and entertainment offerings.

By locating in the heart of the 1,900-acre Port campus-already one of the nation's fastest-growing innovation destinations-the new facility will be at the center of major activities that are transforming the economic trajectory of South Texas.

Spanning a large swath of the former Kelly Air Force Base-where innovations in flight have been launched since the dawn of aviation-the campus has been on an accelerated path as a place where a growing number new technologies are developed. In turn, these breakthroughs are transforming the safety and productivity of key global industries. In addition to aviation, these include manufacturing, information network security, medicine, energy, and supply chains. In the process, as they continue to create jobs, industries based at the Port generate over $5.6 billion in regional economic activity each year.

"Our Board has been hard at work to ensure that the Port serves as a strategic asset for all people in our region," said Port San Antonio Board Chair Chris Alderete.

"Today, we have taken another major step forward in delivering on that promise to create a place that is welcoming to all people in our community," she added. "The innovation center will be a venue that is exciting as it inspires, teaches and helps people connect with new career and business opportunities-from global companies to San Antonio's small business owners who need a place to develop their ideas and market them to the world. We're excited to continue expanding and strengthening a strategic economic growth model that is an example to the nation."

"In an increasingly connected world, there are unprecedented opportunities for innovators who can address today's challenges while opening doors to new systems that benefit all humankind," said Port President and CEO Jim Perschbach.

"From making longstanding industries like transportation and manufacturing safer and more productive to looking at outer space to harness limitless energy for billions of people, we are living in the most exciting moment in the history of technology. To be part of those opportunities, we need to act now and move boldly," he added.

"By building an ecosystem in San Antonio that is exciting and easily accessible to millions of individuals and empowers them so they can be part of that tidal change-through education, through employment and as innovators and entrepreneurs-we keep raising our profile as a leading innovation destination," Perschbach continued. "This will accelerate job and economic growth in our region, and it will increasingly allow us to compete globally based on the value of our technology and the talent of our people."

"The ultimate value of a development project is measured by the positive and lasting impact it has on a community," said Triple-I CEO and Co-CIO David Cibrian. "Our team is tremendously proud to have partnered with Port San Antonio to create a unique and strategic place like no other in the country-able to amplify and grow a vision that has already touched the lives of thousands of families across our community. Together, we look forward on advancing the Port's role as a place for building futures and to also create a proven, robust model that other American communities can draw upon."

Of particular significance, the innovation center will increase the reach of innovative learning experiences that inspire and educate people-from K-12 students to working professionals-and guide them toward career and entrepreneurial pathways involving the tech breakthroughs originating in the region.

Ongoing efforts that will be expanded at the innovation center include the work of the San Antonio Museum of Science and Technology (SAMSAT).

The nonprofit first established its operations on the campus in 2017 in an existing 16,000-square-foot facility (a former military chapel) near the site of the upcoming innovation center. In just three years, the museum has leveraged its initial space and worked closely with all area school districts to deliver innovative STEM/STEAM programs to nearly 50,000 students throughout the region-or about 15,000 children per year.

Nearly 50,000 students have already participated in innovative STEM/STEAM programs at the San Antonio Museum of Science and Technology. The upcoming space will provide capacity to grow the programs ten-fold, including hands-on exhibits like the cybersecurity simulator launched by the museum earlier this year.

Expanded space and amenities at the upcoming innovation center will allow the museum to easily deliver in-person programs to an estimated 150,000 students per year, including hands-on learning on a recently-launched cybersecurity simulator as well as experiences focused on robotics, space science and coding.

SAMSAT will also leverage its new home to support its work in advancing professional training programs for adults. Among these efforts is the museum's recently-launched partnership with numerous area workforce development programs to train thousands of people who recently lost their jobs as a result of the COVID-19 pandemic-allowing them to acquire new skills that are in high demand by technology employers.

"The strongest connector between people and life-changing opportunities is education," said SAMSAT President and CEO Doug King. "For the past three years, our team and scores of supporters and volunteers have been laser focused on using our initial space at the Port to create exciting programs and exhibits that truly attract, engage and inspire."

"We're already seeing the results of those labors, as word has spread throughout our community about the learning experiences and career pathways we're building," he added. "With the upcoming innovation center just a few months away, we are tremendously excited to broaden our reach and have a lasting effect in building people's talent across generations."

The innovation center in the heart of the Port's 1,900-acre campus will be located within 10 minutes southwest of downtown and other major technology hubs in San Antonio. The upcoming facility will be surrounded by a growing array of private- and public-sector employers in leading technologies and the defense sector. San Antonio, dubbed "Military City U.S.A.," is also home to major DoD and other security operations within the Port campus and nearby. They will similarly have access to the innovation center as part of training, demonstrations, and social events. Among them is neighboring Lackland AFB-where nearly 40,000 airmen undergo basic training each year. (Credit: Port San Antonio)

Since Port San Antonio launched its Tech Port blueprint in 2018, employers on the campus have created nearly 4,000 new jobs. More than 80 public- and private-sector organizations operate at the Port, including global names such as Boeing, Booz Allen Hamilton, Lockheed Martin, Northrop Grumman and StandardAero. The campus is also home to local firms that are expanding rapidly as they serve a global clientele, such as CNF Technologies, IPSecure, Knight Aerospace, Plus One Robotics and Reckon Point.

The site also houses major Department of Defense operations, including the Air Force's cybersecurity headquarters (16th Air Force) and other commands that specialize in engineering, environmental science and medical operations.

These and other Port customers continue to fill hundreds of positions in some of the region's best-paid careers, and their expertise has been in growing demand during the COVID-19 pandemic. Furthermore, in an increasingly connected world, their innovations will continue to grow in relevance and applications long past the current global crisis.

Recent examples include Plus One Robotics' systems that are now deployed at FedEx's main hub in Memphis, Tennessee to significantly increase operational capacity and worker safety while creating new careers in robotic network supervision.

Similarly, Knight Aerospace has developed state-of-the-art self-contained medical units that allow for life-saving air transportation of seriously ill and highly contagious patients.

And the Port will soon be home to the Alamo Regional Security Collaboration Center (ARSOC)-the country's first integrated information security operation focused on protection of municipal utilities and other critical infrastructure against growing domestic and international cyberattacks.

The Port is home to startup companies like Reckon Point, whose precision indoor mapping technology has applications that greatly benefit numerous industries, including real estate management, architectural design, supply-chain management in factories and hospitals and even lunar exploration. At the innovation center, similar entrepreneurs can access a scalable research and development / technology lab to design, build and test their new products.

Tech companies at the Port work very closely with area universities and researchers. As an example, Port customer Intertek-one of the world's leading emissions testing services providers-recently collaborated with the University of Texas at San Antonio's Department of Engineering to improve the speed and accuracy of its systems. The upcoming innovation center-especially the tech collaboration / R&D lab-will greatly facilitate these types of projects.

In 2019, the Port and partners that included the San Antonio Economic Development Foundation and City of San Antonio led an industry showcase in Atlanta, Georgia, during one of the world's largest aerospace conferences. There, they presented robotic, artificial intelligence and virtual technologies that have applications to aviation and that were developed by Port customers, Southwest Research Institute and the University of Texas at San Antonio. The industry showroom at the upcoming innovation center will similarly present new technologies to educate and train current and future talent and also to identify private- and public-sector buyers of those products.
 

MEDIA CONTACTS:

Paco Felici (210) 260-3218 | paco.felici@portsanantonio.us
Stephanie Garcia (210) 238-8657 | stephanie.garcia@portsanantonio.us

SOURCE: Port San Antonio

ReleaseID: 602052

Jaguar Health Provides Updates on Investigator-Initiated Trials of Crofelemer (Mytesi)

Company shares updates on investigator-initiated trials of crofelemer (Mytesi®), a novel FDA-approved plant-based oral prescription medicine

SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today provided updates regarding ongoing investigator-initiated trials in non-HIV patient populations of crofelemer (Mytesi®), the novel FDA-approved plant-based oral drug developed and marketed by Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, Inc.

Updates Regarding Investigator-Initiated Trials:

Chronic Idiopathic Diarrhea in Non-HIV Adult Patients

Yield of Diagnostic Tests and Management of Crofelemer for Chronic Idiopathic Diarrhea in Non-HIV Patients: A Pilot Study

Following COVID-related delays, this single-center clinical research study in adult non-HIV patients at The University of Texas Health Science Center at Houston (UTH) has started enrolling. Full enrollment is expected to be reached by the end of 2020, and the study results are expected to be available by mid to late 2021.

Chronic idiopathic diarrhea is a common complaint of patients presenting to family practitioners and internists and is one of the most common reasons for referral to gastroenterologists. It is estimated that the prevalence of chronic idiopathic diarrhea in developed countries (including the U.S.) is approximately 3-5%. It has a significant negative effect on health-related quality of life and causes a high economic burden on patients and society. The American Gastroenterological Association Burden of Illness study (2012) showed that the estimated annual direct and indirect costs associated with chronic idiopathic diarrhea are up to $524 million per year and $136 million per year, respectively.

Functional Diarrhea in Non-HIV Adult Patients

A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of crofelemer in subjects with functional diarrhea

This investigator-initiated study will be conducted at a single center at Beth Israel Deaconess Medical Center, a Harvard Medical School institution in Boston. This study is expected to initiate enrollment of patients in the fourth quarter of 2020, and topline results are expected to be available in fourth quarter of 2021.

Diarrhea in HER2-positive Breast Cancer Patients

HALT-D: Diarrhea Prevention and Prophylaxis with Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel with or without Carboplatin

This is an ongoing investigator-initiated study at Georgetown University to obtain preliminary evidence of the effectiveness of crofelemer for the symptomatic relief of diarrhea in HER2-positive breast cancer patients receiving chemotherapy with trastuzumab, pertuzumab, and docetaxel or paclitaxel with or without carboplatin. The study is nearing completion of enrollment of the full cohort of patients, and subjects in the study are expected to complete treatment by the end of 2020.

The final report for this study is expected to be available in mid-2021.

Mytesi is the only oral plant-based medicine approved by the FDA for the treatment of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Mytesi has a novel mechanism of action that works locally in the gut by gently and effectively modulating and normalizing the flow of water and electrolytes with minimal systemic absorption. Crofelemer comes from the Croton lechleri tree, which is responsibly and sustainably harvested in South America.

SAVE THE DATE:

‘Diarrhea Dialogues: Why bowl control is critical to supportive care in cancer,' Educational Event Scheduled for October 20, 2020

Jaguar will host a virtual ‘Diarrhea Dialogues: Why bowl control is critical to supportive care in cancer,' educational event for investors and business development contacts on Tuesday, October 20, 2020. Leading oncologists, patient advocates, and supportive care experts will address the importance of supportive care for cancer patients as it relates to chronic lower GI tract distress, specifically with regard to debilitating diarrhea experienced as a result of cancer therapy. Jaguar will be issuing further details regarding the event, along with information about how investors and business development contacts can register to participate, as we get closer to the October date.

About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements related to expectations about when investigator-initiated trials will reach full enrollment, and expectations about the timing of the availability of study reports. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

ReleaseID: 602346

StemSation(TM) Reports Revenue Increase of 24% for the Quarter Ending June 30th, 2020

BOCA RATON, FL / ACCESSWIRE / August 19, 2020 / StemSation International, Inc. (OTC PINK:STSN) – a pioneer in the emerging category of dietary supplements called Stem Cell Nutrition, reported revenues for the second quarter ending June 30th , 2020 of $65,405 compared to revenues of $52,675 for the first quarter ending March 31st, 2020, representing an increase of 24% increase.

As start-up expenses subside, overhead costs also decreased by 18% in the second quarter. Ray Carter, StemSation President & CEO commented, "We are pleased to see the positive trends in our financials despite the COVID-19 challenges. We continue to see further growth as we move through Q3 and accelerate our marketing efforts".

StemSation creates and markets all-natural consumer health products that support the two most recently discovered biological systems of the human body – stem cells and endocannabinoids, releasing its first three novel products to support immune health and joint & muscle health.

StemSation continues to expand its product reach globally, currently executing plans to enter the Latin American markets before the end of 2020.

StemSation is a company with a long-term ‘health mission', ambitious research goals, and innovative, holistic approaches to health & wellness, and healthy longevity. Our product line shows a new pathway to wellness.

ABOUT STEMSATION INTERNATIONAL, INC.
StemSation International, Inc. (OTC PINK:STSN) develops, manufactures and distributes natural wellness products that support the stem cell and endocannabinoid systems in the human body through using a direct selling model in which Independent Wellness Advocates ("IWAs") advertise and sell its products directly to consumers. StemSation is headquartered in Boca Raton, Florida and its website can be located at www.stemsation.global.

SAFE HARBOR STATEMENT
This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

FOR INFORMATION, PLEASE CONTACT:
Nicholas B. Panza, Vice President
StemSation International, Inc.
7777 Glades Road
Suite 203
Boca Raton, FL 33434
npanza@stemsationusa.com
(561) 245-7454

SOURCE: StemSation International, Inc.

ReleaseID: 602316

Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute

HARRISON, NY / ACCESSWIRE / August 19, 2020 / Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it was awarded a Small Business Innovative Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to investigate ST101 activity against breast cancer. The grant will provide $255,240 to support research aimed at characterizing the pharmacokinetic profile and optimal dosing regimen of ST101 for treatment of breast cancer, with a focus on metastatic disease. Patients with metastatic breast cancer currently have very limited treatment options and average 5-year survival of 22%.

"We are very pleased to have received this highly competitive grant from the NCI," said Jim Rotolo, Ph.D., Head of Research of Sapience Therapeutics. "This award validates the potential of ST101 as a novel therapeutic for breast cancer and enables us to dig deeper and explore specific opportunities within metastatic and triple negative breast cancer, two areas of high unmet need."

ST101 is a peptide antagonist of the transcription factor C/EBPβ, which drives tumor cell proliferation and survival in a variety of human malignancies, including breast cancer. Preclinical studies of ST101 have demonstrated in vitro cell kill across a wide range of breast cancer subtypes, including triple negative breast cancer. ST101 has also demonstrated significant in vivo activity against hormone receptor positive (HRpos) breast tumors in preclinical testing. Sapience plans to include locally advanced/metastatic HRpos breast cancer as an expansion cohort in its Phase 1/2 trial of ST101, which commenced in July 2020.

This grant was awarded by the National Cancer Institute of the National Institutes of Health under Award Number R43CA250786. The content of this press release is solely the responsibility of the author and does not necessarily represent the official views of the NIH.

About Sapience Therapeutics

Sapience Therapeutics, Inc., is a privately held, clinical stage biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. With platform-based discovery of peptide therapeutics that disrupt protein-protein interactions, Sapience's molecules hold potential to target intracellular interactions that are traditionally considered "undruggable targets". Its lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies.

Forward-Looking Statements

This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience's product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

Contacts

Sapience Therapeutics, Inc.:
Barry Kappel, Ph.D., M.B.A.
President and Chief Executive Officer
info@sapiencetherapeutics.com

SOURCE: Sapience Therapeutics, Inc.

ReleaseID: 602315

Dielectric Gases Market to Expand 1.8x through 2030; Sharp Dip in Industrial Activities During Covid-19 Pandemic Hits Short-term Prospects, says Fact.MR

Dielectric gas manufacturers are pushing for strategic collaborations in research to widen scope of end use applications, in efforts to generate new, lucrative revenue streams.

ROCKVILLE, MD / ACCESSWIRE / August 19, 2020 / The dielectric gases market is estimated to rise 1.8x with a very healthy 7% CAGR between 2020 and 2030. The coronavirus pandemic is anticipated to have a detrimental impact on the dielectric gases industry. This can be attributed to the sharp reduction in industrial and commercial activity around the world during the crisis period, which in turn has limited electricity usage, and the requirement for dielectric gases in high-voltage applications.

"The rising popularity of compact substations, with growing bias towards reduction of cost space, and maintenance, along with superior operational performance and smaller product specifications are favoring the adoption of dielectric gases in high voltage devices throughout the projection period," says the Fact.MR analyst.

Dielectric Gases Market – Important Takeaways

Compressed air is rapidly gaining traction for dielectric barrier properties, with strong demand in substation applications.
HVAC and office equipment applications are witnessing strong growth, particularly for telecom and IT infrastructure.
Europe is projected to hold major market share through the forecast period owing to the presence of leading market players and major production facilities.

Request a report sample to gain more market insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4805

Dielectric Gases Market – Driving Factors

Strong growth in residential construction, and development of power and telecom infrastructure supports demand.
Demand for safe and eco-friendly alternatives to conventional oil insulation provides impetus to market growth.

Dielectric Gases Market – Leading Constraints

High dependency of the industry on international supply chains, and imposed tariffs hurt market prospects.
Slow technological advancements in dielectric gases, especially in emerging economies is holding back market growth.

Anticipated Market Impact by Coronavirus Outbreak

The global dielectric gases market is going through a short-term downturn during the coronavirus contagion outbreak. With primary applications in high-voltage power industry settings, low energy demand during the coronavirus crisis has also hurt demand for dielectric gases. Further, Niche applications in commercial infrastructure buildings, and oil & gas facilities have also been hit by the outbreak, reducing short term sales prospects for dielectric gases. However, the industry is likely to recover strongly towards the end of 2020, with growing relaxation on lockdown regulations and research on new fields of application.

Explore the global dielectric gases market with 198 figures, 86 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/4805/dielectric-gases-market

Competition Landscape

Leading manufacturers in the consolidated dielectric gases market include but are not limited to Linde AG, 3M Company, Showa Denko K.K., and Solvay S.A.

Leading manufacturers in the dielectric gases market have been observed investing extensively in product innovations aimed towards performance enhancements, new applications, and eco-friendly characteristics.

For instance, General Electric in collaboration with 3M Company has developed a ready to go dielectric gas mixture as sulfur hexafluoride substitute for high voltage electricity transmission. Microsoft has announced a patent hermetically sealed datacenters with high pressure dielectric gas. ABB has set up the first eco-efficient gas insulated switchgear alternative.

More on the Report

The FACT.MR's market research report provides in-depth insights on dielectric gases market. The market is scrutinized according to gas type (SF6, dry air, fluoronitrile, nitrogen, fluoroketones, and others), application (medium, high, extra & ultra-high voltage), end use equipment (switch gears, transformers, and gas insulated lines), and end use industry (transport, heavy metals, oil & gas, mining, chemicals & petrochemicals, power utilities, and others) across six key regions (North America, Latin America, Europe, East Asia, South Asia & Oceania, and Middle East and Africa).

Explore Wide-ranging Coverage of FACT.MR's Chemical & Materials Landscape

Dielectric Fluids Market: Find insights on the Dielectric Fluids market with analysis of segments, statistics, influencers, market players and strategies adopted over a 10-year forecast period.

Polyphenylene Sulfide (PPS) Resins Market: FACT.MR's report on the polyphenylene sulfide (PPS) resins market offers insights on the market set for strong growth during 2019-2029, including restraining forces, revenue sources, market leaders, and market strategies.

Dielectric Ceramics Market: Read an analysis on the Dielectric Ceramics market with insights on growth factors, opportunities, restraints, regional market forecast, regulatory policies, and strengths of market leaders.

About Fact.MR

Fact.MR is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Fact.MR is headquartered in Dublin, Ireland, and has delivery centers in the U.S. and India. FACT.MR's latest chemicals market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1575/global-dielectric-gases-market

SOURCE: FactMR

ReleaseID: 602384

MTS Announces Q2 2020 Results

MOSCOW, RUSSIA / ACCESSWIRE / August 19, 2020 / Mobile TeleSystems PJSC (NYSE:MBT)

Q2 2020

in RUB bn unless indicated otherwise

MTS Group – Key figures*

 
Q2 2020
 
 
Q2 2019
 
Change,%
 

Revenue

 
117.7
 
 
116.2
 
 
1.3
%

o/w Russia

 
116.3
 
 
115.3
 
 
0.8
%

Adjusted OIBDA[1]

 
51.6
 
 
51.3
 
 
0.6
%

o/w Russia

 
50.4
 
 
50.3
 
 
0.3
%

Operating profit

 
26.0
 
 
27.1
 
 
-4.2
%

Profit attributable to owners of the Company

 
11.8
 
 
12.7
 
 
-7.5
%

Cash CAPEX[2]

 
20.6
 
 
22.7
 
 
-9.1
%

Net debt[3]

 
282.5
 
 
310.1
 
 
-8.9
%

Net debt / LTM Adjusted OIBDA[4]

 
1.3
x
 
1.4
x
 
n/a
 

H1 2020 highlights

 
H1 2020
 
 
H1 2019
 
Change, %
 

Operating cash flow

 
64.6
 
 
4.9
 
 
13
x

Free cash flow

 
24.8
 
 
-32.9
 
 
n/a
 

Free cash flow excl. SEC/DOJ payment

 
24.8
 
 
22.7
 
 
9.2
%

*All profit & loss figures for 2019 have been restated to reflect the deconsolidation of MTS's former Ukraine operations

Alexey Kornya, President & CEO, commented on the results:

"As the world navigates 2020, two things have become crystal clear: connectivity has never been so essential, and digital transformation is accelerating like never before. These trends only further reaffirm MTS's long-term strategy to maintain a leading network while moving forward to capture new opportunities in segments beyond connectivity.

Despite facing some challenges as a result of the COVID-19 pandemic, I am happy to report that MTS delivered positive top-line growth in Q2 2020. Group revenue increased 1.3% to reach 117.7 billion rubles, with major positive contributions from MTS Bank as well as core connectivity. In addition, we saw Group adj. OIBDA notch upward 0.6% to 51.6 billion rubles, with negative COVID-19 impacts in roaming and banking more than offset by positive contributions from core services, OPEX savings in retail, and other factors.

While some uncertainty and headwinds remain – in particular lower levels of international roaming as we enter peak summer travel season – we now have some additional clarity as we head further into the second half of the year. Given our proven record of core resilience, continued operational agility, and sustained demand for connectivity services, we are reaffirming our earlier full-year 2020 guidance of flat to 3% growth in revenue, -2% to flat in Adjusted OIBDA, and cash CAPEX of around RUB 90 bn."

More information at: http://ir.mts.ru/investors/financial-center/financial-results/default.aspx

[1] Adjusted OIBDA doesn't include a loss from impairment of non-current assets of RUB 0.9 bn for Q2 2020

[2] Excluding costs of RUB 0.02 bn related to the purchase of 4G licenses in Armenia in H1 2019

[3] Excluding lease obligations

[4] Including the effects of IFRS 15 and 16

SOURCE: Mobile TeleSystems PJSC via EQS Newswire

ReleaseID: 602388

Prospera Increases its Interest in Saskatchewan Oil and Gas Properties

CALGARY, AB / ACCESSWIRE / August 19, 2020 / Prospera Energy Inc. ("Prospera" or the "Corporation") (TSXV:PEI)(FRA:OF6A) Prospera wishes to update and advise shareholders on a key acquisitional agreement.

The Corporation is pleased to announce that it has entered into an Agreement whereby Prospera Energy is increasing its total asset holdings and interest at the Hearts Hills and Luseland properties. On August 17, 2020 Prospera has signed an agreement for the acquisition of an additional 40% net working interest from participating interest holders in the southwest Saskatchewan Hearts Hills and Luseland properties. The purchase price will be satisfied by a reduction of the vendors arrears for operational costs of $1,017,711.00, subject to normal accounting adjustments. Prospera will now increase its overall net working interest in these properties from 50% to 90%, a 450% increase from the 20% net working interest that was originally acquired on June 11, 2018. The properties are located approximately 330 kilometers east of Calgary.

The Corporation remains the operator of all wells and facilities on the Properties and is continuing the accelerated development of production on all properties through further well reactivations and workovers. Prospera will be issuing a further update to shareholders when the transaction closes.

Prospera further announces that at the Corporation's annual general meeting of shareholders, held on June 29, 2020, in Calgary, it has granted and issued an aggregate of 800,000 incentive stock options. A director of the Corporation, Mel Clifford, has been issued 300,000 options and two of the Corporation's consultants have been issued 250,000 options each. The stock options were granted in accordance with the Corporation's stock option plan and are exercisable for a period of five years from the date of issuance at an exercise price of $0.05 per share.

About Prospera

Prospera Energy Inc. is a Canadian natural resource Corporation engaged in the acquisition, exploration, development and production of oil and gas properties with operations in Alberta and western Saskatchewan.

For further information:

Sarshar Ahmad
Interim Chief Executive Officer & Director

Email: sahmad@prosperaenergy.com
Tel: (403)454-9010
Website: www.prosperaenergy.com

Production volumes are commonly expressed on a barrel of oil equivalent ("BOE") basis whereby natural gas volumes are converted at a ratio of six thousand cubic feet to one barrel of oil. The intention is to convert oil and natural gas measurement units into one basis for improved analysis of results and comparisons with other industry participants. The term BOE may be misleading, particularly if used in isolation. The conversion ratio is based on an energy equivalent method and does not represent an economic value equivalency at the wellhead.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements relating to the future operations of the Corporation and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding future plans and objectives of the Corporation, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements

Although Prospera believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Prospera can give no assurance that they will prove to be correct. Since forward- looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, risks associated with the oil and gas industry in general (e.g., operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of reserve estimates; the uncertainty of estimates and projections relating to production, costs and expenses, and health, safety and environmental risks), commodity price and exchange rate fluctuations and uncertainties resulting from potential delays or changes in plans with respect to exploration or development projects or capital expenditures.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Prospera. As a result, Prospera cannot guarantee that any forward- looking statement will materialize and the reader is cautioned not to place undue reliance on any forward- looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and Prospera does not undertake any obligation to update publicly or to revise any of the included forward- looking statements, whether as a result of new information, future events or otherwise, except as expressly required by Canadian securities law.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Prospera Energy Inc.

ReleaseID: 602352

Quad M Solutions and Rejuvenan Global Health Offer Jointly Digital Healthcare Insurance Coverage for the Gig Economy Workers

EDGEWATER, NJ / ACCESSWIRE / August 19, 2020 / Quad M Solutions, Inc. (OTC PINK:MMMM) ("Quad M" or the "Company"), a public holding company whose operating subsidiaries, offer staffing services and employee benefits such as health plans, HR-human resources, and payroll services, to small and mid-sized group employers, is pleased to announce the offering of a new health insurance product line empowered by a licensing agreement with Rejuvenan Global Health ("Rejuvenan"). Rejuvenan is a provider of advanced Telehealth services including personalized wellness programs coupled with its 24/7/365 Telemedicine consultations with physicians covering all the 50 U.S. states.

Quad M Solutions will integrate Rejuvenan's telemedicine and clinical wellness services into the health benefit plans it designed for its ever-growing universe of self-insured users, including but not limited to its relationships with EdLogics, BenefitHub, eHome Counseling Management Partners, LLC, Orchestra Rx and VoiceSense. Quad M and Rejuvenan also plan on developing a joint venture that would combine their respective services based upon certain performance measures.

Pat Dileo, Quad M's Chief Executive Officer, commented, "We are extremely excited to work with Rejuvenan, as we share a vision in creating a modern health insurance product for the gig economy. Technology-driven healthcare coverage drives down costs and increases availability to individuals and small group. Rejuvenan provides great support in preventive care and wellness of our covered lives as well as helping us with our medical underwriting to lower premium costs for employees and employers. We expect the integrated product offering with Rejuvenan to be fully operational by early Q4 2020. We look forward to working with Fred Nazem and his first-rate team."

Fred Nazem, Rejuvenan's Founder and Executive Chairman, stated, "This agreement is a milestone achievement for both companies. Together we will take the lead in a movement to make healthcare affordable and manageable for small and mid-size employers and their employees. This product is particularly suited for the burgeoning gig economy population. The timing is very good as it coincides with our expansion in New York City, serving the elderly and the under insured populations. The aging population and the increasing movement toward a gig economy in New York City are ideal areas for this solution. Our team is eagerly looking forward to working with Pat and his impressive team at Quad M Solutions."

About Rejuvenan Global Health, Inc.

Rejuvenan Global Health, Inc. ("Rejuvenan) is a truly unique digital personal health and wellness company, providing personalized Wellness programs and Telemedicine consultations. The company's core mission is to utilize digital interventions to deliver clinically proven behavioral modifications that prevent, treat and reverse lifestyle-induced chronic diseases through a combination of proprietary algorithms that incorporate the 2009 Nobel Prize-winning science of telomere biology. The company also offers on demand access to board-certified MD's. Rejuvenan provides its members curated, personalized coaching and other interactive tools that drive behavioral change through the adoption of healthy lifestyle and a focus on the four pillars of health: nutrition, fitness, stress management and social support. For Quad M, and its affiliates, Rejuvenan has created a platform to be integrated with its various health insurance benefit programs providing its members with on demand medical care, personalized health scoring, nutrition, fitness and mental health services focusing on the "Whole Health" of a member, not just the disease.

Rejuvenan founder, Fred Nazem, has been building highly disruptive, industry-leading healthcare and technology companies since the late 1970's. He Co-founded billion-dollar enterprises such as Cirrus Logic (OTC: CRUS), Blue Bird Bio (OTC: BLUE) and Concord Health/Genesis Health Ventures. He is best known as the turnaround specialist who led the successful reorganization of Oxford Health Plans, which was later sold to United Healthcare for about $6 billion.

For additional information on Rejuvenan Global Health, please visit: https://www.rejuvenan.com

About Quad M Solutions, Inc.

Quad M Solutions, Inc. (‘Quad M') is a company that offers self-insured health plans, staffing, HR-human resources, payroll services and worker's compensation insurance to small and mid-size group employers (1-500 employees), and to members of the exploding essential worker ('gig economy') labor market. Four subsidiary companies, NuAxess 2, Inc., PrimeAxess, Inc., OpenAxess, Inc. and PrimeAxess 2, Inc. are all instrumental in accomplishing our mission.

Our self-insured programs are consumer-driven and technology-leveraged, both of which makes them transparent, affordable and responsive to the healthcare retirement needs of employees who are looking for the highest quality benefits, integrated health information and better medical provider access and outcomes.

Quad M's strategic partners bring comprehensive consumer-driven health and wellness focused services that are linked to our websites, mobile applications, wearable devices, remote monitoring, and other health- related tools, all of which broaden the value proposition offered to employees.

For additional information, please visit: QuadMSolutions.com and NuAxess.com.

Forward-looking Statements:

The statements contained herein that are not historical facts are forward-looking statements within the meaning of the federal securities laws (Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). You can identify such forward-looking statements by the words "expects," "intends," "plans," "projects," "believes," "estimates," "likely," "possibly," "probably," "goal," "opportunity," "objective," "target," "assume," "outlook," "guidance," "predicts," "appears," "indicator" and similar expressions. Forward-looking statements involve a number of risks and uncertainties. In the normal course of business, Quad M Solutions, in an effort to help keep our stockholders and the public informed about our operations, may from time to time issue such forward-looking statements, either orally or in writing. Generally, these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of such plans or strategies, or projections involving anticipated revenues, earnings, profits, pricing, operating expenses or other aspects of operating results. We base the forward-looking statements on our expectations, estimates, and projections at the time such statements are made. These statements are not guarantees of future performance and involve risks and uncertainties that we cannot predict. In addition, we have based many of these forward-looking statements on assumptions about future events that may prove to be inaccurate. The actual results of the future events described in such forward-looking statements could differ materially from those stated in such forward-looking statements.

Corporate Contact:

Pat Dileo 
CEO, Chairman 
Quad M Solutions, Inc.
M 732-423-5520
www.nuaxess.com

Fred Nazem
Founder and Executive Chairman, 
Rejuvenan Global Health, Inc.
O 212-486-8010
www.rejuvenan.com 

Investors:
IR@QuadMsolutions.com

SOURCE: Quad M Solutions, Inc. 

ReleaseID: 602282